Background
==========

Acute myocardial infarction is one of the leading causes of death in the world which is caused by coronary artery thrombosis. Platelets play a central role in cardiovascular thrombosis. Platelet aggregation caused due to a ruptured artherosclerotic plaque could eventually lead to vascular occlusion. Another important component of vascular diseases is inflammation. During inflammation, prostaglandins (PG) like PGI~2~, PGE~2~ and PGD~2~ are released which are also involved in thrombosis. Lower concentrations of PGE~2~ enhance platelet aggregation whereas higher concentrations inhibit aggregation. PGE~2~ acts via 4 receptors: EP~1~, EP~2~, EP~3~ and EP~4~ (G~s~ signalling). The role of the EP~3~ receptor in enhancing platelet activation and aggregation has been looked at in detail but the role of the EP~4~ receptor is largely unknown. We were interested in how this receptor modulates platelet aggregation and what are the signalling mechanisms involved in this process.

Methods
=======

Platelet aggregation assays were performed *ex vivo* using a platelet aggregation analyser (Aggregometer II). Blood from healthy human donors was used to obtain platelet-rich plasma. Aggregation was induced using ADP or collagen. Different agonists and antagonists were added to investigate their effects on platelet aggregation. Ca^2+^ flux changes caused by addition of agonists were also examined using a fluorescent Ca^2+^ dye (Fluo-3) by flow cytometry. Expression of the EP~4~ receptor on the surface of platelets was established using indirect flow cytometry whereas expression of CD62P, PAC1 and CD41 was examined using direct flow cytometry. *In vitro* thrombus formation was assessed by flowing whole blood on collagen-coated Cellix biochips at −30 dyne/cm^2^ using the Mirus nanopump.

Results
=======

We observed that human platelets express EP~4~ receptors. A selective EP~4~ agonist potently inhibited the platelet aggregation as induced by ADP or collagen. This effect could be completely reversed by using an EP~4~ antagonist, but not by PGI~2~, PGD~2~ TXA~2~ receptor antagonists. Moreover, an EP~4~ antagonist enhanced the PGE~2~-induced stimulation of platelet aggregation, indicating a potent anti-aggregatory activity of the EP~4~ receptors. Interestingly, the inhibitory effect of the EP~4~ agonist was brought about by protein kinase C but not adenylyl cyclase, accompanied by attenuated Ca^2+^ flux, decreased activation of glycoprotein IIb/IIIa and down-regulation of P-selectin. Most importantly, *in vitro* thrombus formation was effectively reduced by the EP~4~ agonist and this effect was reversed using the EP~4~ antagonist.

Conclusions
===========

These findings indicate that the EP~4~ receptor is a potential biological drug target in anti-platelet therapy.
